Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus IBUPROHM COLD AND SINUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus IBUPROHM COLD AND SINUS.
COXANTO vs IBUPROHM COLD AND SINUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
1 g intravenous every 6 hours.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%.
Category C
Category C
NSAID
NSAID/Decongestant Combination